157 related articles for article (PubMed ID: 27180428)
1. DESIGN, SYNTHESIS AND BIOLOGICAL EVALUATION OF NEW PYRROLOAZEPINES WITH POTENTIAL AND SELECTIVE ANTITUMOR ACTIVITY.
Jaiash DA; Belal A; Abdelgawad MA; Abdellatif KR
Acta Pol Pharm; 2016; 73(2):359-68. PubMed ID: 27180428
[TBL] [Abstract][Full Text] [Related]
2. Design, synthesis and anticancer activity evaluation of some novel pyrrolo[1,2-a]azepine derivatives.
Belal A
Arch Pharm (Weinheim); 2014 Jul; 347(7):515-22. PubMed ID: 24729464
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis, and docking studies of phenylpicolinamide derivatives bearing 1H-pyrrolo[2,3-b]pyridine moiety as c-Met inhibitors.
Zhu W; Wang W; Xu S; Tang Q; Luo R; Wang M; Gong P; Zheng P
Bioorg Med Chem; 2016 Feb; 24(4):812-9. PubMed ID: 26810712
[TBL] [Abstract][Full Text] [Related]
4. Pyrrolizines: Design, synthesis, anticancer evaluation and investigation of the potential mechanism of action.
Gouda AM; Abdelazeem AH; Omar HA; Abdalla AN; Abourehab MAS; Ali HI
Bioorg Med Chem; 2017 Oct; 25(20):5637-5651. PubMed ID: 28916158
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, and molecular docking studies of 2-(furan-2-yl)quinazolin-4-one derivatives as potential antiproliferative agents.
Ahmed MF; Belal A
Arch Pharm (Weinheim); 2015 Jul; 348(7):487-97. PubMed ID: 25921702
[TBL] [Abstract][Full Text] [Related]
6. Synthesis, molecular docking and antitumor activity of novel pyrrolizines with potential as EGFR-TK inhibitors.
Belal A
Bioorg Chem; 2015 Apr; 59():124-9. PubMed ID: 25748126
[TBL] [Abstract][Full Text] [Related]
7. Synthesis, biological evaluation and molecular docking studies of pyrazole derivatives coupling with a thiourea moiety as novel CDKs inhibitors.
Sun J; Lv XH; Qiu HY; Wang YT; Du QR; Li DD; Yang YH; Zhu HL
Eur J Med Chem; 2013 Oct; 68():1-9. PubMed ID: 23933045
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and biological evaluation of N9-cis-cyclobutylpurine derivatives for use as cyclin-dependent kinase (CDK) inhibitors.
Park SJ; Kim E; Yoo M; Lee JY; Park CH; Hwang JY; Ha JD
Bioorg Med Chem Lett; 2017 Sep; 27(18):4399-4404. PubMed ID: 28827110
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and CHK1 inhibitory potency of Hymenialdisine analogues.
Parmentier JG; Portevin B; Golsteyn RM; Pierré A; Hickman J; Gloanec P; De Nanteuil G
Bioorg Med Chem Lett; 2009 Feb; 19(3):841-4. PubMed ID: 19111462
[TBL] [Abstract][Full Text] [Related]
10. Synthesis, and docking studies of phenylpyrimidine-carboxamide derivatives bearing 1H-pyrrolo[2,3-b]pyridine moiety as c-Met inhibitors.
Zhu W; Wang W; Xu S; Wang J; Tang Q; Wu C; Zhao Y; Zheng P
Bioorg Med Chem; 2016 Apr; 24(8):1749-56. PubMed ID: 26964675
[TBL] [Abstract][Full Text] [Related]
11. Synthesis of Novel Hybrids Inspired from Bromopyrrole Alkaloids Inhibiting MMP-2 and -12 as Antineoplastic Agents.
Rane RA; Naphade SS; Bangalore PK; Palkar MB; Patel HM; Shaikh MS; Alwan WS; Karpoormath R
Chem Biol Drug Des; 2015 Aug; 86(2):210-22. PubMed ID: 25418204
[TBL] [Abstract][Full Text] [Related]
12. Design and synthesis of 4-(2,3-dihydro-1H-benzo[d]pyrrolo[1,2-a]imidazol-7-yl)-N-(5-(piperazin-1-ylmethyl)pyridine-2-yl)pyrimidin-2-amine as a highly potent and selective cyclin-dependent kinases 4 and 6 inhibitors and the discovery of structure-activity relationships.
Wang Y; Liu WJ; Yin L; Li H; Chen ZH; Zhu DX; Song XQ; Cheng ZZ; Song P; Wang Z; Li ZG
Bioorg Med Chem Lett; 2018 Mar; 28(5):974-978. PubMed ID: 29429832
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and biological activities of 4-substituted pyrrolo[2,3-a]carbazole Pim kinase inhibitors.
Giraud F; Akué-Gédu R; Nauton L; Candelon N; Debiton E; Théry V; Anizon F; Moreau P
Eur J Med Chem; 2012 Oct; 56():225-36. PubMed ID: 22982527
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis, and evaluation of non-ATP-competitive small-molecule Polo-like kinase 1 (Plk1) inhibitors.
Chen DX; Huang J; Liu M; Xu YG; Jiang C
Arch Pharm (Weinheim); 2015 Jan; 348(1):2-9. PubMed ID: 25430493
[TBL] [Abstract][Full Text] [Related]
15. QSAR based docking studies of marine algal anticancer compounds as inhibitors of protein kinase B (PKBβ).
Davis GD; Vasanthi AH
Eur J Pharm Sci; 2015 Aug; 76():110-8. PubMed ID: 25936945
[TBL] [Abstract][Full Text] [Related]
16. Design and synthesis of benzimidazole analogs endowed with oxadiazole as selective COX-2 inhibitor.
Rathore A; Rahman MU; Siddiqui AA; Ali A; Shaharyar M
Arch Pharm (Weinheim); 2014 Dec; 347(12):923-35. PubMed ID: 25303727
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis and biological evaluation of 7H-pyrrolo[2,3-d]pyrimidine derivatives containing 1,8-naphthyridine-4-one fragment.
Zhang J; Chen P; Duan Y; Xiong H; Li H; Zeng Y; Liang G; Tang Q; Wu D
Eur J Med Chem; 2021 Apr; 215():113273. PubMed ID: 33601310
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and biological evaluation of 4-phenoxy-6,7-disubstituted quinolines possessing semicarbazone scaffolds as selective c-Met inhibitors.
Qi B; Tao H; Wu D; Bai J; Shi Y; Gong P
Arch Pharm (Weinheim); 2013 Aug; 346(8):596-609. PubMed ID: 23843304
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and biological evaluation of selective and potent cyclin-dependent kinase inhibitors.
N'gompaza-Diarra J; Bettayeb K; Gresh N; Meijer L; Oumata N
Eur J Med Chem; 2012 Oct; 56():210-6. PubMed ID: 22982525
[TBL] [Abstract][Full Text] [Related]
20. Design, synthesis, and docking studies of afatinib analogs bearing cinnamamide moiety as potent EGFR inhibitors.
Tu Y; OuYang Y; Xu S; Zhu Y; Li G; Sun C; Zheng P; Zhu W
Bioorg Med Chem; 2016 Apr; 24(7):1495-503. PubMed ID: 26906472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
